Investor News

Investor-News M1 Kliniken AG

2018

18. December 2018 - M1 Kliniken AG starts international expansion: Specialist Centre for Aesthetic Medicine opened in Vienna

M1 Kliniken AG starts international expansion: Specialist Centre for Aesthetic Medicine opened in Vienna

  • Market leader for beauty medicine in Germany sees a strong growth in Europe’s attractive growth opportunities
  • Potential for up to 10 locations in Austria and Switzerland alone
  • More than 20 specialist centres to be opened in Europe by the end of 2020

Berlin, 18.12.2018 – M1 Kliniken AG (ISIN: DE000A0STSQ8), market leader in the field of beauty medicine in Germany, has opened the first “M1 Med Beauty” specialist centre outside its home market in Vienna. In the Austrian capital, M1’s experienced specialists are now available for all aspects of aesthetic medicine. The M1 Group has thus begun its international expansion. Numerous countries in Europe offer attractive growth opportunities. The number of M1 Beauty specialist centres is to be more than doubled from the current 24 to 50 by the end of 2020. At least 20 locations are planned in Europe.

“Similar to Germany, the markets for beauty medicine are highly fragmented and expensive in virtually all Western European countries. Having developed M1 into the market leader in Germany in just a few years, we want to take advantage of the attractive environment and grow significantly in Europe in the future,” says Patrick Brenske, Member of the Management Board of M1 Kliniken AG.

High treatment quality with low costs at the same time due to specialization
Since the beginning of its expansion in 2015, the M1 Group has been the first company in the industry to focus on specialization. The advantage: high treatment quality at low costs. Centralized purchasing enables the use of state-of-the-art technical infrastructure and top-quality products at a low price. In addition, a high utilization of the premises and the medical technology is achieved. M1 passes on these cost advantages – which will increase even more as the company grows – to its customers and at the same time maintains high medical quality. For example, M1 has founded its own academy for the further training of its now more than 60 employeed doctors. This is rewarded by the customers: In 2017, around 70 percent of customers were not with M1 for the first time.

More than 20 specialist centres planned throughout Europe by the end of 2020
Now that M1 has successfully completed the extensive approval procedure for the Vienna location, the opening of further locations in Austria is planned. In addition, the focus in the coming years will be on Switzerland, the Netherlands and Great Britain. In all countries, M1 will make high-quality aesthetic medicine available to a larger population group at attractive prices and thus increase market volumes. A total of more than 20 specialist centres for aesthetic medicine are to be opened in European countries outside Germany by the end of 2020. M1 has already secured financing for its international expansion through a capital increase carried out in September 2018. This also applies to growth financing in Germany. In addition to other M1 Med Beauty locations, the Group has already prepared for expansion into the areas of aesthetic dentistry and laser treatment under the new “M1 Dental” and “M1 Laser” brands.

Download as PDF

Weiter lesen

22. November 2018 - M1 Kliniken AG opens further specialist centres: Market leader in beauty medicine remains on course for expansion in 2018

M1 Kliniken AG opens further specialist centres: Market leader in beauty medicine remains on course for expansion in 2018

  • Expansion 2018 on schedule: The number of specialist centres will increase by more than 30%
  • Entry into aesthetic dentistry market well received by patients
  • Conditions created for further significant increases in sales in the coming year

Berlin, 22.11.2018 – M1 Kliniken AG (ISIN: DE000A0STSQ8), the number 1 in the field of beauty medicine in Germany, continues its expansion course in 2018. 4 new specialist centres have been opened so far this year. Two more are to follow by the end of the year. The M1 Group will thus operate a total of 24 specialist centres for aesthetic treatments by the end of 2018. The increase of more than 30% compared to the previous year is in line with corporate planning. M1 Kliniken AG is thus creating the conditions for a further significant increase in sales in the coming year.

While M1 already opened its second location in Munich and Hamburg, the company premiered in Dresden. In October, the M1 Med Beauty specialist centre opened at the idyllic Jüdenhof 9 square in the state capital of Saxony. The modern premises are located directly in the historic old town near the famous Frauenkirche, Dresden’s landmark.

In addition, the first treatment centre for aesthetic dentistry was opened in Berlin in early 2018. With the brand “M1 Dental”, the company offers bleaching treatments, ceramic veneers for permanently straight and white teeth as well as transparent braces for ‘inconspicuous’ tooth correction. Also in this range M1 sets landmarks in quality and price. The range of services is to be expanded step by step.

“Beauty medicine has arrived in the middle of society and the demand is constantly increasing. We are pleased that we can make a contribution to market penetration with our high-quality treatments at fair prices,” says Patrick Brenske, member of the Management Board of M1 Kliniken AG. “Our entry into the dental market was very well received by our patients and we will start our nationwide expansion in the coming months”.

Download as PDF

Weiter lesen

12. September 2018 - M1 Kliniken AG successfully completes capital increase

M1 Kliniken AG successfully completes capital increase.

M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) has successfully completed the capital increase in accordance with the resolutions passed on September 10, 2018 and today.

The Company increased its share capital by € 1,000,000.00 to € 17,500,000.00 by issuing a total of 1,000,000 no-par value bearer shares in exchange for cash contributions, to the exclusion of shareholders’ statutory subscription rights, making partial use of authorized capital 2018. The new shares are entitled to dividends as of January 1, 2018.

The placement price determined by the Company’s Management Board with the approval of the Supervisory Board was € 15.30 per share. Due to the high demand, the new shares were sold to institutional investors as part of an accelerated private placement process. Subject to registration of the capital increase in the commercial register, M1 Kliniken AG will receive gross proceeds of approximately € 15,300,000.00 million from the capital increase.

The new shares are to be included in the open market trading of the Frankfurt Stock Exchange (Basic Standard) without a prospectus. Delivery and settlement of the new shares is expected to take place on September 17, 2018.

The capital increase was accompanied by B. Metzler seel. Sohn & Co. KGaA.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the construction of additional M1 Med-Beauty locations.

M1 Kliniken AG
The Board of Directors

Important information:

The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.

In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to “qualified investors” within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Download as PDF

Weiter lesen

10. September 2018 - Decides to implement a cash capital increase

M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.

Berlin, September 10, 2018 – The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today decided to increase the company’s share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 10,2018 by partially utilizing the authorized capital 2018. The Supervisory Board has approved the Management Board’s decision.

The share capital of the company is to be increased – by the partial utilization of the authorized capital 2018 of currently € 16,500,000.00 – by issuing up to 1,650,000 bearer shares to a total share capital of up to € 18,150,000.00. The new shares are to be eligible for dividends as of January 1,2018 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company’s shares. The placement price will not be significantly lower than the market price.

The final placement volume and the placement share price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and will be announced in a separate ad hoc announcement.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance its expansion into new medical indications as well as the opening of additional M1-locations in Germany and abroad.

M1 Kliniken AG
The Board of Directors

Important information:

The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.

In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to “qualified investors” within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Download as PDF

Weiter lesen

27. August 2018 - On growth path with top-class medicine: M1 Kliniken AG increases sales by +30 % in the first half of 2018

On growth path with top-class medicine: M1 Kliniken AG increases sales by +30% in the first half of 2018 

 – Sales EUR 28.9 million (H1/17: EUR 22.3 million)

– EBT EUR 4.28 million (H1/17: EUR 4.24 million); margin within target corridor

– Investments made for further growth: New specialty centers, new treatment areas and international expansion in the second half of 2018

– Positive outlook: sales and earnings to be further increased

Berlin, 27.08.2018 – M1 Kliniken AG (ISIN: DE000A0STSQ8) continued its growth path in the first half of 2018 and increased sales by 30% from EUR 22.3 million to EUR 28.9 million. As the leading private provider of health services in the field of beauty medicine in Germany, the group is benefiting with its brand “M1 Med Beauty” from the growing demand for plastic and aesthetic treatments.

“The utilisation of our 20 ambulatory specialist centres for beauty treatments and the Schlossklinik in Berlin has developed satisfactorily. After opening five specialist centers in the second half of 2017, we were able to put two more centers into operation in the first half of this year,” says Dr. Walter von Horstig, member of the Management Board of M1 Kliniken AG. “In addition to operational growth, we have also invested in the future. Among other things, we opened the first center for aesthetic dental treatment in our clinic in Berlin. In recent months we have been able to establish medical and business processes in order to quickly expand throughout Germany with the new “M1 Dental” brand.“

Despite the up-front costs of the large number of new locations and investments in new treatment areas, the M1 Group continues to grow profitably: earnings before tax (EBT) in the first half of 2018 were at EUR 4.3 million  (H1 2017: EUR 4.2 million). The EBT margin is thus in the targeted corridor.

Positive outlook: New specialist centres, entry into aesthetic dentistry and international expansion

M1 Kliniken is confident about the second half of 2018 and beyond. As a result of the specialist centers currently in operation, sales and EBT will continue to rise compared with the same period of the previous year and the first half of the year. Further locations are also planned. The range of services for cosmetic treatments is to be expanded in all specialist centres. In addition, the first locations for aesthetic dental treatments are to be opened in major German cities. Finally, M1 is working on its internationalisation. The first foreign location is to be opened in Vienna in the second half of 2018.

“The market for plastic and aesthetic treatments continues to offer significant growth potential to the M1 Group. This applies to our existing treatments and, of course, to new markets. With our strategy – top-class medicine at a fair price – we will continue to promote innovations and actively develop markets in the future,” says Patrick Brenske, member of the Management Board of M1 Kliniken AG. “We will also roll out our business model internationally and make M1 the leading beauty brand in Europe.“

Download as PDF

Weiter lesen

22. March 2018 - Preliminary Results 2017: M1 Kliniken AG increases profit (EBT) by 36.4% in 2017. On growth track with top-class aesthetic medicine

M1 Kliniken AG increases profit (EBT) by 36.4% in 2017: On growth track with top-class aesthetic medicine

– Preliminary figures 2017: Sales EUR 47.2 million (+31.1%), EBT EUR 7.4 million (+36.4%)
– Number of specialist centres increased from 11 to 17, alone 5 in Q4
– Positive outlook: increase in sales and profits also planned for 2018

Berlin, 22.03.2018 – On growth track with top-class aesthetic medicine: M1 Kliniken AG (ISIN: DE000A0STSQ8), the leading private provider of health services in the field of beauty medicine in Germany, has again significantly increased its sales and profits in 2017. According to unaudited figures, sales increased by 31.1% from EUR 36.0 million in 2016 to EUR 47.2 million in the previous year. The result from ordinary activities (EBT) rose by 36.4% from EUR 5.5 million in 2016 to EUR 7.4 million.

The M1 Group’s growth driver is “M1 Med Beauty”, the leading brand for aesthetic and plastic treatments in Germany. In 2017, the number of specialist centres in Germany increased by more than 50% from 11 to 17. The number of treatments also increased significantly from 100,000 to over 150,000. Five specialist centres ­– Wiesbaden, Münster, Berlin II and III and Mannheim – were opened in the fourth quarter alone. M1 has thus already created the basis for further sales and earnings growth in the current year. In addition, a second location was opened in Munich in the first weeks of 2018, and larger premises were moved into in Frankfurt. The group now operates a Germany-wide network of 19 specialist centres for beauty treatments and, with the Schlossklinik in Berlin the largest and most modern specialist clinic for plastic and aesthetic medicine in Europe.

“In 2017, we again succeeded in significantly expanding our capacities and at the same time growing profitably. We intend to continue along this path in the coming years. The potential for this is there”, says Patrick Brenske. “Our specialisation is the basis for the highest quality, and we are the first in Germany to implement this consistently and successfully within the field of beauty medicine.“ In the further course of 2018, the M1 Group plans to open numerous new locations and begin its international expansion. In addition, the company sees great market potential in other areas of aesthetic and plastic medicine. Accordingly, the range of services offered by the specialist centres is to be expanded.

Download as PDF

Weiter lesen

27. February 2018 - Growing demand for beauty treatments: M1 Kliniken AG continues growth and opens new specialist centre for aesthetic medicine

Growing demand for beauty treatments: M1 Kliniken AG continues growth and opens new specialist centre for aesthetic medicine

  • Second location opened in Munich and moved into larger location in Frankfurt am Main
  • Number of specialist centres increased from 11 to 17 in 2017
  • Numerous further specialist centres and start of international expansion planned

Berlin, 27.02.2018 – The demand for plastic and aesthetic beauty treatments in Germany has also risen in 2017. This benefits M1 Kliniken AG (ISIN: DE000A0STSQ8), which is the number one in the field of beauty medicine in Germany under its “M1 Med Beauty” brand. In 2017 alone, the number of specialist centres in Germany increased by more than 50% from 11 to 17. Treatments also increased significantly last year from 100,000 in 2016 to more than 150,000 – and the trend continues to rise sharply.

The Group continues to grow in the first few weeks of the new year. M1 Med Beauty opened its second specialist centre in Munich. In addition to the previous location in Schwabing, M1 now operates a further centre with experienced specialists for all questions relating to aesthetic medicine and plastic surgery at the location Stachus (Sonnenstraße 11). In addition, the specialist centre in Frankfurt am Main has moved to Schillerstraße. The reason: The high demand can be better served in larger premises.

„We are very pleased with the strong demand for our high-quality treatments. It shows that our specialisation in selected aesthetic and plastic treatments is the right strategy. We will continue our growth course in the current year – and beyond – and open numerous new locations,” says Patrick Brenske, member of the management board of M1 Kliniken AG. „With the opening of our first specialist centre outside Germany, we also intend to start our international expansion in 2018.“

Download as PDF

Weiter lesen

2017

5. October 2017 - M1 Kliniken AG successfully completes capital increase

M1 Kliniken AG successfully completes capital increase.

M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) has successfully completed the capital increase in accordance with the resolutions passed yesterday and today. The capital increase was oversubscribed several times.

The Company increased its share capital by € 1,500,000.00 to € 16,500,000.00 by issuing a total of 1,500,000 no-par value bearer shares in exchange for cash contributions, to the exclusion of shareholders’ statutory subscription rights, making partial use of authorized capital 2015. The new shares are entitled to dividends as of January 1,2017.

The capital increase was carried out to the maximum possible extent. The placement price determined by the Company’s Management Board with the approval of the Supervisory Board was € 11.00 per share. Due to the high demand, the new shares were sold to institutional investors as part of an accelerated private placement process. Subject to registration of the capital increase in the commercial register, M1 Klinken AG will receive gross proceeds of approximately € 16,500,000.00 from the capital increase.

The new shares are to be included in the open market trading of the Frankfurt Stock Exchange (Basic Standard) without a prospectus. Delivery and settlement of the new shares is expected to take place on October 11, 2017.

The capital increase was accompanied by B. Metzler seel. Sohn & Co. KGaA.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the construction of additional M1 Med-Beauty locations.

M1 Kliniken AG
The Board of Directors

Important information:

The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.

In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to “qualified investors” within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Language:                   English
Company:                   M1 Kliniken AG
Grünauer Str. 1
12557 Berlin
Germany

Phone:                        +49 (0)30-887086225
Fax:                             +49 (0)30-887086228
E-Mail:                         ir@m1-kliniken.de
Internet:                       www.m1-kliniken.de

ISIN:                            DE000A0STSQ8
WKN:                          A0STSQ
Stock exchanges:         Frankfurt, Stuttgart, Düsseldorf, Xetra

Weiter lesen

4. October 2017 - cash capital increase to finance further growth investments

M1 Kliniken AG decides to carry out a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments.

The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today resolved to increase the company’s share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 2,2015 with the approval of the Supervisory Board and partially utilizing the authorized capital 2015.

The share capital of the company is to be increased by the partial utilization of the authorized capital 2015 of currently € 15,000,000.00 by issuing up to 1,500,000 bearer shares to a total of up to € 16,500,000.00. The new shares are to be eligible for dividends as of January 1,2017 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company’s shares. The placement price will not be significantly lower than the market price.

The final placement volume and the placement price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and announced in a separate ad hoc announcement.

M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the opening of additional M1 Med-Beauty locations.

M1 Kliniken AG
The Board of Directors

Important information:

The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.

In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to “qualified investors” within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.

Language:                  English
Company:                   M1 Kliniken AG
Grünauer Str. 1
12557 Berlin
Germany

Phone:                        +49 (0)30-887086225
Fax:                             +49 (0)30-887086228
E-Mail:                         ir@m1-kliniken.de
Internet:                       www.m1-kliniken.de
ISIN:                             DE000A0STSQ8
WKN:                           A0STSQ
Stock exchanges:         Frankfurt, Stuttgart, Düsseldorf, Xetra

Weiter lesen

27. September 2017 - M1 Kliniken AG strengthens management team – Dr. Walter von Horstig appointed to the Management Board

M1 Kliniken AG strengthens management team – Dr. Walter von Horstig appointed to the Management Board

M1 Kliniken AG announces that the company’s Supervisory Board has appointed Dr. Walter von Horstig to the Management Board of the company effective October 1,2017. Together with Patrick Brenske, he will drive the further growth and development of the company.

Dr. von Horstig has studied business administration and has extensive experience in the healthcare industry. Since April 2017 he has been successfully working as managing director of M1 Med Beauty Berlin GmbH. Before that, for seven years he was managing director of a DRK Blood Donation Service and has led the company to renewed growth.

Dr. Albert Wahl, Chairman of the Supervisory Board of M1 Kliniken AG, comments on the decision as follows: “As a young and fast-growing company, M1 has to concentrate on the expansion of its own product and service offering with a focus on quality and efficiency for the benefit of patients. With Dr. von Horstig, we have found an ideal fit with profound industry knowledge.”

Dr. von Horstig adds: “I am looking forward to the exciting task and the challenges of working with the M1 team to achieve the goals set by the company.

Weiter lesen

31. August 2017 - Half-year report 2017

Release of half-year earnings 2017

Berlin, 31.08.2017 (pta024/31.08.2017/11:11) – M1 Kliniken AG will publish its interim report in the course of the day. A strong first half-year is the basis for the continuation of the company’s growth:

• Sales growth of 20 % compared to previous year’s figures to EUR 22.3 million
• Operating profit increases by 36 % compared to previous year’s figures to EUR 4.2 million
• EBIT margin rises to just under 19 %

M1 Kliniken AG, the operator of the largest inpatient clinic for aesthetic breast surgery in Germany, has developed very satisfactorily as a result of increasing demand for plastic and aesthetic beauty treatments due to its price and quality leadership.

Revenues in the reporting period rose by 20 % to EUR 22.3 million. On this basis, an EBIT of EUR 4.2 million was achieved, which exceeded the previous year’s result by 36 % and almost matched the EBIT of the full previous year (EUR 4.4 million). The EBIT margin rose to just under 19 %.

With currently more than 100,000 treatments per year, M1 Kliniken AG remains on a successful
growth path. Another medical center was opened in Leipzig in March 2017, and further openings will follow in the second half of 2017. The development of our own M1-beauty product line started in the first half-year. Marketing is expected to begin in the coming financial year. The transfer of the business model to similar segments in the health care sector for self-payers is currently being examined.

On June 30, 2017, a dividend of Eur 0.30 / share was paid to the shareholders. The operational
development of the company in the second half of the year will be characterized by the
establishment of further medical centers.

In August 2017, Bankhaus Metzler began the coverage of M1 Kliniken AG for the first time. In its initial assessment, the bank recommends the “Buy” recommendation. The price target is EUR 16.00.

Weiter lesen

8. May 2017 - M1 Kliniken AG continues its expansion

M1 Kliniken AG continues its expansion

Berlin, 08.05.2017/08:00 – M1 Kliniken AG, ISIN: DE000A0STSQ8, announces the acquisition of a building for a surgery center in Essen, Germany.

M1 Kliniken AG has acquired a property with 2,000 square meters in the city center of Essen (Germany) and is planning to build a new surgery center there. The location of Essen and the surrounding cities and municipalities has almost the same potential as the existing M1 Beauty Clinic in Berlin-Köpenick, which is expected to reach its capacity limits in 2017. The new operations center in Essen will complement the surrounding M1 Beauty sites in Düsseldorf and Cologne. It also targets patients from the western neighbors Belgium and from the Netherlands.

The M1 concept, to offer the best quality with affordable access to aesthetic medicine, is very well received by the customers. The Schlossklinik in Berlin, with six operating rooms and 35 patient beds, as well as the nationwide 13 M1 specialist centers, are very popular. The expansion of existing locations and the establishment of new locations in Germany and Europe remain a priority for the company group in the further course of 2017.

Weiter lesen

30. March 2017 - Preliminary IFRS results 2016

Berlin, 31.03.2017/08:00 – M1 Kliniken AG, ISIN: DE000A0STSQ8, announces its preliminary IFRS result for 2016.

  • During the reporting period the preliminary annual net income was €5,455,893.52, with earnings per share of €0.36 (annual net income for previous year: €6,631,000, €0.44 earnings per share).
  • The dividend should be 30 cents per share as in the previous year.
  • Equity increased to €30,705,804.39 (previous year: €29,750,000).
  • The equity ratio increased from 90% to 94%.

In 2016 the Frankfurt Stock Exchange listed M1 Kliniken AG again reported a successful fiscal year. The company increased its sales to €36,546,000.

The clinic in Berlin was expanded to six operating rooms and 35 patient beds. During the reporting period 13 M1 specialist centres were available nationwide following additional openings. The M1 concept of offering top quality and affordable access to aesthetic medicine is well received by clients; as a result M1 has ascended to become a leading provider in this area.

M1 Group uses the economies of scale to make further optimisations in product selection, development and marketing of branded products to doctors, pharmacists and wholesalers.

The Board will recommend a dividend of 30 cents per share (previous year: 30 cents per share) to the shareholders’ meeting.

In 2017 M1 Group will continue to invest in the quality of services. This includes digitisation, further training for specialist personnel and the continuous development of quality standards. The company aims to increase sales by 20%.

Current opportunities for growth will be realised by expanding existing sites and establishing new sites in Germany and Europe.

Weiter lesen

2016

29. August 2016 - H1 2016

H1 2016: Preliminary IFRS results, sales EUR 18.5 million, operating result (EBIT) EUR 3.0 million; investments in the expansion of hospital capacities and outpatient services

In the first half-year 2016 M1 Kliniken AG, Berlin (ISIN: DEA0STSQ8), achieved IFRS Group sales of EUR 18.5 million (previous year total: EUR 34.9 million) and an operating result (EBIT) of EUR 3.0 million (previous year total: EUR 7.0 million).

„The clinic in Berlin received on April 14th 2016 the concession for the enlargement to six operating rooms and 34 patient beds. In Germany we are now active with twelve M1-outpatient service centres. The expansion of capacities will allow M1 further growth in the course of the year 2016”, says Patrick Brenske, Member of the Management Board of M1 Kliniken AG.

Weiter lesen

Contact

M1 Kliniken AG
Grünauer Straße 5
12557 Berlin

P/ + 49 (0) 30 347 47 44 14
F/ + 49 (0) 30 347 47 44 17
E/ ir@m1-kliniken.de